Valeant Pharma (VRX) Trades at New Lows Amid Ex-Executive Probe
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Valeant Pharma (NYSE: VRX) is trading at fresh 52-week lows following reports ex-CEO, Michael Pearson and ex.-CFO, Howard Schiller, are the focus of criminal probe related potential accounting fraud tied to the company's hidden Philidor Rx Services company.
Shares last traded down 12.4% to $17.83.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stocks with call price movement; VRX VXX
- Alphabet (GOOGL) January weekly volatility increases into Q4 and outlook
- TransDigm (TDG) Valeant Comparison 'Nothing New', Tweet Risk Low and Would Use Weakness to Buy - Credit Suisse
Create E-mail Alert Related CategoriesShort Sales, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!